Chemi, Francesca
,
Rothwell, Dominic G.
McGranahan, Nicholas
Gulati, Sakshi
Abbosh, Chris
Pearce, Simon P. http://orcid.org/0000-0002-1680-5538
Zhou, Cong
Wilson, Gareth A.
Jamal-Hanjani, Mariam
Birkbak, Nicolai
Pierce, Jackie
Kim, Chang Sik
Ferdous, Saba
Burt, Deborah J.
Slane-Tan, Daniel
Gomes, Fabio
Moore, David
Shah, Rajesh
Al Bakir, Maise
Hiley, Crispin
Veeriah, Selvaraju
Summers, Yvonne
Crosbie, Philip
Ward, Sophia
Mesquita, Barbara
Dynowski, Marek
Biswas, Dhruva http://orcid.org/0000-0001-9141-5188
Tugwood, Jonathan
Blackhall, Fiona
Miller, Crispin
Hackshaw, Allan
Brady, Ged http://orcid.org/0000-0002-5009-8814
Swanton, Charles http://orcid.org/0000-0002-4299-3018
Dive, Caroline http://orcid.org/0000-0002-1726-8850
Funding for this research was provided by:
Cancer Research UK (A27412, A25254, C11496/A17786)
Innovative Medicines Initiative (115749-CANCER-ID)
Fondazione Internazionale Menarini
Article History
Received: 9 July 2019
Accepted: 20 August 2019
First Online: 7 October 2019
Change Date: 3 June 2020
Change Type: Correction
Change Details: An amendment to this paper has been published and can be accessed via a link at the top of the paper.
Competing interests
: C.D. receives research grants/support from AstraZeneca, Astex Pharmaceuticals, Bioven, Amgen, Carrick Therapeutics, Merck, Taiho Oncology, GSK, Bayer, Boehringer Ingelheim, Roche, BMS, Novartis, Celgene and Epigene Therapeutics, Menarini, Angle PLC and Clearbridge Biomedics, all of which are outside the scope of this paper. C.D. has received honoraria/consultancy fees from Biocartis, Merck and AstraZeneca and Illumina, again outside the scope of this work. C.S. receives grant support from Pfizer, AstraZeneca, BMS and Roche-Ventana, Boehringer-Ingelheim. C.S. has consulted for Pfizer, Novartis, GlaxoSmithKline, MSD, BMS, Celgene, AstraZeneca, Illumina, Genentech, Roche-Ventana, GRAIL, Medicxi and the Sarah Cannon Research Institute and is an adviser for Dynamo Therapeutics. C.S. is a shareholder of Apogen Biotechnologies, Epic Bioscience and GRAIL, and has stock options in and is cofounder of Achilles Therapeutics.